UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 136

Sortiert nach

Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis

Internal Medicine, 2022/09/01, Vol.61(17), pp.2655-2660

2022

Link zum Volltext

Verfügbarkeit prüfen

Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study

Acta medica Okayama, 2021-08, Vol.75 (4), p.461-469

2021

Link zum Volltext

Verfügbarkeit prüfen

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Haematologica (Roma), 2021-04, Vol.106 (4), p.1182-1187

2021

Link zum Volltext

Verfügbarkeit prüfen

Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707

Haematologica (Roma), 2017-12, Vol.102 (12), p.2097-2103

2017

Link zum Volltext

Verfügbarkeit prüfen

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years

Nagoya journal of medical science, 2022-02, Vol.84 (1), p.80-90

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia

Blood, 2013-04, Vol.121 (16), p.3095-3102

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial

Acta medica Okayama, 2019-12, Vol.73 (6), p.547-552

2019

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

Haematologica (Roma), 2010-11, Vol.95 (11), p.1857-1864

2010

Link zum Volltext

Verfügbarkeit prüfen

Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation

Transplantation and cellular therapy, 2022-02, Vol.28 (2), p.76-82

2022

Link zum Volltext

Verfügbarkeit prüfen

Diffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy

Internal Medicine, 2014, Vol.53(16), pp.1809-1812

2014

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Blood, 2020-11, Vol.136 (Supplement 1), p.37-38

2020

Link zum Volltext

Verfügbarkeit prüfen

Case of Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis

Internal Medicine, 2022, pp.8422-21

2022

Link zum Volltext

Verfügbarkeit prüfen

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.3260-3260

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma

Acta haematologica, 2021-05, Vol.144 (3), p.264-274

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment strategy in untreated transplant-eligible multiple myeloma patients

Rinshō ketsueki, 2016, Vol.57 (10), p.2064

Sunami, Kazutaka

2016

Link zum Volltext

Verfügbarkeit prüfen

OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e270-e271

2019

Link zum Volltext

Verfügbarkeit prüfen

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

The Lancet (British edition), 2019-12, Vol.394 (10214), p.2096-2107

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Blood, 2016-12, Vol.128 (22), p.3315-3315

2016

Link zum Volltext

Verfügbarkeit prüfen

Antileukemic

Nihon rinshō, 2015-02, Vol.73 Suppl 2, p.191

2015

Link zum Volltext

Verfügbarkeit prüfen

Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma

British journal of haematology, 2008-12, Vol.143 (5), p.672-680

2008

Link zum Volltext

Verfügbarkeit prüfen

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society

Oncotarget, 2019-01, Vol.10 (5), p.595-605

2019

Link zum Volltext

Verfügbarkeit prüfen

Proposal of Progressive Adult Onset EBV-Associated Lymphoproliferative Disorder (PAEBV) as a Rapid-Onset Neoplastic Disease

Blood, 2009-11, Vol.114 (22), p.2920-2920

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 136

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLink Journals

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(124)

Publikationsform

Artikel
(136)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(52)
Humans
(48)
Life Sciences & Biomedicine
(48)
Hematology
(33)
Aged
(27)
Male
(26)
Middle Aged
(25)
Female
(24)
Adult
(19)
Multiple Myeloma
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Multiple Myeloma - Drug Therapy
(15)
Retrospective Studies
(13)
Dexamethasone
(10)
General & Internal Medicine
(10)
Medicine, General & Internal
(10)
Aged, 80 And Over
(9)
Patients
(9)
Transplantation, Autologous
(9)
Treatment Outcome
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(45)
Clinical Lymphoma, Myeloma And Leukemia
(8)
Haematologica
(6)
British Journal Of Haematology
(5)
Internal Medicine
(5)
Rinsho Ketsueki
(5)
Rinshō Ketsueki
(5)
Acta Haematologica
(4)
Cancer Science
(4)
Journal Of Cardiac Failure
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis

Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years

Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia

Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

P929: CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE

Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation

Diffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy

Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients

Case of Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma

Treatment strategy in untreated transplant-eligible multiple myeloma patients

OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Antileukemic

Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society

Proposal of Progressive Adult Onset EBV-Associated Lymphoproliferative Disorder (PAEBV) as a Rapid-Onset Neoplastic Disease

Aktive Filter

Suchergebnisse filtern